← Leaderboards
D Craig Allred
Baylor College Of Medicine
$2,257,762
Attributed
$2,257,762
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $276.3K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,257,762 · 7
By mechanism
P01$1,424,592 · 4
P30$639,822 · 1
U19$193,348 · 1
P50$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Daniel None Medina$5,636,236
- C Kent Osborne$24,386,086
- Yi Li$11,171,360
- Suzanne A Fuqua$14,426,929
- Wen-Hwa Lee$10,566,748
Others in their field
Top investigators on “Breast Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$347,312,063
- Norman Wolmark · Nsabp Foundation, Inc.$251,848,784
- Richard L Schilsky · University Of Chicago$110,812,897
- Walter John Curran · Thomas Jefferson University$96,881,565
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$87,504,493
- Monica M Bertagnolli · Strang Cancer Prevention Center$84,613,341
Research focus
Breast NeoplasmsImmunocytochemistryHistopathologyHuman TissueCancer RiskGrowth FactorPrognosisBiomedical FacilityOncogenesGene ExpressionNeoplasm /Cancer Remission /RegressionTissue /Cell PreparationCarcinogenesis InhibitorCell CycleHuman SubjectDissectionPreneoplastic StateBiomarkerChemopreventionNeoplasm /Cancer ChemotherapyCancer PreventionTamoxifenBiopsyWestern Blottings
Grant awards (25)
Core--Pathology and Tissue Resource$276,322
P01 · FY2008 · CA · contact PI
Core--Pathology and Tissue Resource$275,571
P01 · FY2007 · CA · contact PI
Core--Pathology and Tissue Resource$174,034
P01 · FY2006 · CA · contact PI
Core--Pathology and Tissue Resource$170,059
P01 · FY2005 · CA
Core--Pathology and Tissue Resource$165,632
P01 · FY2004 · CA
CORE--PATHOLOGY$254,104
P30 · FY2002 · CA
DEVELOPMENTAL &PROGNOSTIC FACTORS IN PREMALIGNANT BREAST DISEASE$0
P01 · FY2002 · CA
CORE--MICRODISSECTION$0
P01 · FY2002 · CA
CORE--HISTOPATHOLOGY$0
P01 · FY2002 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2002 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2002 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2002 · CA
CORE--PATHOLOGY$0
U19 · FY2002 · CA
CORE--PATHOLOGY$254,104
P30 · FY2001 · CA
DEVELOPMENTAL &PROGNOSTIC FACTORS IN PREMALIGNANT BREAST DISEASE$0
P01 · FY2001 · CA
CORE--PATHOLOGY$0
U19 · FY2001 · CA
CORE--MICRODISSECTION$0
P01 · FY2001 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2001 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2001 · CA
CORE--PATHOLOGY$193,348
U19 · FY2000 · CA
DEVELOPMENTAL &PROGNOSTIC FACTORS IN PREMALIGNANT BREAST DISEASE$181,487
P01 · FY2000 · CA
CORE--MICRODISSECTION$181,487
P01 · FY2000 · CA
CORE--PATHOLOGY$131,614
P30 · FY2000 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2000 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2000 · CA